2012 pay: $11 million
2011 pay: $6.8 million
Since taking over for longtime CEO William Weldon, Alex Gorsky has presided over a sea change at Johnson & Johnson ($JNJ): Under his watch, devices and diagnostics have become the company's largest businesses, outpacing pharma by a combined more than $2 billion in revenue in 2012. Driving that growth was J&J's $21.3 billion buyout of Synthes, closed in 2012, which contributed to a 34.3% jump in orthopedics revenue.
And while J&J posted 6.4% device revenue growth in 2012, the company has been beset by a litany of recalls and resultant lawsuits, spending about $800 million in the fourth quarter alone to deal with the fallout over all-metal hips and vaginal meshes. At the same time, the drug, device and consumer products giant is mulling over just what to do with its diagnostics business, with Gorsky publicly wondering whether to keep, sell or spin off the unit.
In 2012, Gorsky hauled in a base salary of $1.1 million, $2.8 million in stock awards, $1.5 million in options and $3.4 million in nonequity incentives, plus J&J tacked about $2.1 million on to his pension.
- read J&J's proxy (PDF)